OPKO Health Stock-Based Compensation 2010-2024 | OPK
OPKO Health stock-based compensation from 2010 to 2024. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
| OPKO Health Annual Stock-Based Compensation (Millions of US $) |
|
|---|---|
| 2024 | $11 |
| 2023 | $11 |
| 2022 | $19 |
| 2021 | $14 |
| 2020 | $9 |
| 2019 | $13 |
| 2018 | $22 |
| 2017 | $28 |
| 2016 | $43 |
| 2015 | $26 |
| 2014 | $15 |
| 2013 | $11 |
| 2012 | $5 |
| 2011 | $7 |
| 2010 | $7 |
| 2009 | $4 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.930B | $0.713B |
| OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The company's pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy induced nausea and vomiting. OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel. | |||